• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Clover Health Celebrates the Election of Dr. Ian Duncan, Clover MA Board Member, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries

    9/18/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care
    Get the next $CLOV alert in real time by email

    WILMINGTON, Del., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today celebrates the appointment of Dr. Ian Duncan, Ph.D., FSA, FIA, FCIA, FCA, CSPA MAAA, a member of Clover's Medicare Advantage Board of Directors, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries (SOA). On September 12, 2025, the SOA announced that Dr. Duncan will become the 78th President and Chair at the 2026 SOA ImpACT Annual Conference.

    With roots dating back to 1889, the SOA is the world's largest actuarial professional organization, with more than 34,000 members worldwide. The SOA advances actuaries as leaders in measuring and managing risk to improve financial outcomes for individuals, organizations and the public.

    Clover Health has been privileged to benefit from Dr. Duncan's expertise and guidance as a member of its Medicare Advantage subsidiary's Board of Directors. His pioneering work in predictive analytics and health risk adjustment has helped transform how the industry at large approaches value-based care, benefiting millions of patients nationwide. Dr. Duncan's deep experience in predictive modeling and healthcare analytics continues to inform the Company's approach to improving care for Medicare beneficiaries through technology and data-driven insights.

    "Congratulations to Ian on this exceptional honor," said Andrew Toy, CEO of Clover Health. "His leadership has shaped the field of health analytics and risk adjustment for decades. This election is a win not just for actuaries, but for anyone working to build a more data-informed healthcare system."

    Dr. Duncan's election to lead the Society of Actuaries comes at a time when the profession is expanding its influence across new industries and applications. His vision for modernizing actuarial education and promoting entrepreneurship within the profession has already begun to inspire a new generation of actuaries to pursue innovative career paths.

    "It's an incredible honor to be elected by my peers to lead the Society of Actuaries," said Ian Duncan, Ph.D., FSA, MAAA. "This is a moment for the actuarial profession to lean into innovation - applying new methods, new technologies, and new ways of thinking to some of healthcare's biggest challenges. At Clover, I see firsthand how combining actuarial science with modern data tools can transform care, and I look forward to bringing that same focus to my work at the SOA."

    Dr. Duncan is Adjunct Professor of Actuarial Statistics at the University of California, Santa Barbara. He has founded or co-founded five companies, most recently Santa Barbara Actuaries Inc., which merged with Arbital Health in 2023. His career has focused on advancing actuarial applications in health care, particularly in predictive modeling and health risk adjustment. He has authored more than 80 peer-reviewed papers and several books and chapters, including Healthcare Risk Adjustment and Predictive Modeling and Managing and Evaluating Healthcare Intervention Programs.

    Dr. Duncan earned a Ph.D. in actuarial statistics from Heriot-Watt University, Edinburgh, and a graduate degree in economics from Balliol College, Oxford.

    About Clover Health:

    Clover Health (NASDAQ:CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology's impact on Medication Adherence, Congestive Heart Failure, and Chronic Obstructive Pulmonary Disease as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

    Visit: www.cloverhealth.com

    Investor Relations:

    Ryan Schmidt

    [email protected]

    Press Inquiries:

    [email protected]



    Primary Logo

    Get the next $CLOV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLOV

    DatePrice TargetRatingAnalyst
    12/17/2024$6.00Buy
    Craig Hallum
    10/7/2024$4.00Neutral
    UBS
    2/25/2022$3.00 → $2.50Market Perform
    SVB Leerink
    2/2/2022$7.00 → $3.00Underperform → Market Perform
    Cowen & Co.
    2/2/2022$6.00Buy
    Canaccord Genuity
    1/19/2022$3.00Market Perform
    SVB Leerink
    1/10/2022$9.00 → $3.50Neutral
    Citigroup
    1/7/2022$9.00 → $3.50Neutral → Underperform
    Credit Suisse
    More analyst ratings

    $CLOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Clover Health with a new price target

    Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00

    12/17/24 8:33:41 AM ET
    $CLOV
    Medical Specialities
    Health Care

    UBS initiated coverage on Clover Health with a new price target

    UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00

    10/7/24 7:45:42 AM ET
    $CLOV
    Medical Specialities
    Health Care

    SVB Leerink reiterated coverage on Clover Health Investments with a new price target

    SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously

    2/25/22 5:03:33 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Loengard Anna U bought $68,755 worth of shares (26,500 units at $2.59) (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/14/25 4:44:26 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Garipalli Vivek bought $998,997 worth of shares (446,980 units at $2.23), increasing direct ownership by 32% to 1,856,247 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/8/25 4:07:07 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Garipalli Vivek bought $999,596 worth of shares (531,700 units at $1.88), increasing direct ownership by 61% to 1,409,267 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/13/24 4:06:53 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, Medicare Advantage Reynoso Jamie L. sold $5,332 worth of shares (2,012 units at $2.65) and covered exercise/tax liability with 8,706 shares, decreasing direct ownership by 0.35% to 3,043,172 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    10/7/25 4:37:42 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Chief Executive Officer Toy Andrew covered exercise/tax liability with 308,950 shares, decreasing direct ownership by 3% to 10,165,562 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    10/3/25 4:10:15 PM ET
    $CLOV
    Medical Specialities
    Health Care

    CEO, Medicare Advantage Reynoso Jamie L. sold $15,184 worth of shares (4,914 units at $3.09), decreasing direct ownership by 0.16% to 3,053,890 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    9/19/25 4:13:04 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clover Health Comments on 2026 Medicare Advantage Star Ratings and Trajectory for Increasing Profitability into 2027

    Company underscores differentiated business model; reiterates confidence in its ability to drive above-market membership growth and increasing Adjusted EBITDA profitability1 through 2027, independent of Star ratings WILMINGTON, Del., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today commented on the Centers for Medicare & Medicaid Services ("CMS") release of the 2026 Star ratings for Clover Health's Medicare Advantage ("MA") plans. CMS has awarded the Clover PPO MA plans with 3.5 Stars and Clover's HMO M

    10/9/25 4:55:03 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health to Report Third Quarter 2025 Financial Results on November 4, 2025

    WILMINGTON, Del., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today announced that it will release its financial results after the market closes on Tuesday, November 4, 2025. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. Third Quarter 2025 Conference Webcast Details: What: Clover Health's Third Quarter 2025 Earnings Conference CallWhen: Tuesday, November 4, 2025, at 5:00 p.m

    10/7/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Counterpart Health Expands Leadership to Accelerate Enterprise Partnerships and Regional Adoption of AI-Powered Platform Counterpart Assistant

    SAN FRANCISCO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI‑powered physician‑enablement platform, today announced that Blaine Lindsey, Vice President of Enterprise Growth and Partnerships and Shannon Jacobs, President of Market Operations for the Gulf Region have joined Counterpart Health. These two strategic leadership appointments are integral to nurturing new partnerships and ensuring operational support for successful adoption of Counterpart Assistant (CA). These appointments come during a time when many physicians l

    10/6/25 4:30:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    SEC Filings

    View All

    Clover Health Investments Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    10/9/25 4:56:28 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Investments Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    8/11/25 4:31:21 PM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Clover Health Investments Corp.

    10-Q - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    8/8/25 8:12:56 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Leadership Updates

    Live Leadership Updates

    View All

    Clover Health Celebrates the Election of Dr. Ian Duncan, Clover MA Board Member, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries

    WILMINGTON, Del., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today celebrates the appointment of Dr. Ian Duncan, Ph.D., FSA, FIA, FCIA, FCA, CSPA MAAA, a member of Clover's Medicare Advantage Board of Directors, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries (SOA). On September 12, 2025, the SOA announced that Dr. Duncan will become the 78th President and Chair at the 2026 SOA ImpACT Annual Conference. With roots dating back to 1889, the SOA is the world's largest actuarial

    9/18/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution

    WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today announced the appointment of Vicky Bruner as Vice President of Operations. As Counterpart scales to meet growing demand from payors and providers nationwide, Bruner will lead several critical functions including customer implementations, provider network engagement, clinician onboarding and training, and longitudinal account support. Her work will be foundational, ensuring operational readiness and delivery consisten

    7/29/25 4:30:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Appoints Joseph Oldakowski as Vice President of Finance and Controller

    WILMINGTON, Del., July 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), a physician enablement company bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph (Joe) Oldakowski as Vice President of Finance and Controller. In this role, Mr. Oldakowski reports to Chief Financial Officer Peter Kuipers and will lead Clover's corporate accounting, GAAP, SEC, and statutory financial reporting and tax function. Mr. Oldakowski, who joined Clover Health in June, brings nearly two decades of experience in finance and accounting leadership across the healthcare and insurance sectors. He most recently served a

    7/17/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Financials

    Live finance-specific insights

    View All

    Clover Health to Report Third Quarter 2025 Financial Results on November 4, 2025

    WILMINGTON, Del., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today announced that it will release its financial results after the market closes on Tuesday, November 4, 2025. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. Third Quarter 2025 Conference Webcast Details: What: Clover Health's Third Quarter 2025 Earnings Conference CallWhen: Tuesday, November 4, 2025, at 5:00 p.m

    10/7/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth

    Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-yearSecond quarter 2025 Total revenues of $478 million, up 34% year-over-yearSecond quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $17 million, and Adjusted Net income of $17 million Updates Full Year 2025 Guidance: Increases Average Medicare Advantage membership to 104,000 - 108,000, representing 32% growth year-over-year at the midpointMaintains Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointImproves Adjusted SG&A to between $335 million and $345 million, representing Adjusted SG&A as a percentage

    8/5/25 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health to Report Second Quarter 2025 Financial Results on August 5, 2025

    WILMINGTON, Del., July 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Tuesday, August 5, 2025. Company management will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. Second Quarter 2025 Conference Call and Webcast Details: What: Clover Health's Second Quarter 2025 Earnings Conference CallWhen: Tuesday, August 5, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-245-3047 (for U.S. caller

    7/8/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    11/12/24 2:31:31 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    11/4/24 11:25:56 AM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Clover Health Investments Corp. (Amendment)

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    7/7/23 4:35:52 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care